Medigene AG

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Market Closed - Xetra Other stock markets 11:36:01 2024-05-17 am EDT			5-day change	1st Jan Change
1.405 ^EUR	-0.71%		-2.43%	-7.87%

May. 15	Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	CI
May. 14	Medigene Ag Maintains Earnings Guidance for 2024	CI

Medigene AG Reaffirms Revenue Guidance for the Year 2020

November 12, 2020 at 01:31 am EST

Medigene AG reaffirmed revenue guidance for the year 2020. The Company continues to expect total revenues of EUR 7 million to EUR 9 million.

Latest news about Medigene AG

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS	May. 15	CI
Medigene Ag Maintains Earnings Guidance for 2024	May. 14	CI
Medigene Boosts Share Capital Via Rights Offering, Private Placement	May. 08	MT
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 - Targeted T Cell Receptor	May. 02	CI
Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein	May. 02	CI
Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process	Apr. 25	CI
Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024	Apr. 08	CI
Medigene Gets European Patent for T-Cell Receptor Technology	Apr. 04	MT
Medigene AG Secures European Patent for Its iM-TCR Technology	Apr. 04	CI
Medigene AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Medigene AG, 2023 Earnings Call, Mar 28, 2024	Mar. 28
Medigene Ag Provides Earnings Guidance for 2024	Mar. 28	CI
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy	Mar. 04	CI
Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors	Feb. 12	CI
Medigene AG Maintains Financial Guidance for the Fiscal Year 2023	Nov. 21	CI
Medigene Presents New Data for MDG 2011, the First TCR in a Novel Kras Library	Nov. 04	CI
Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing	23-10-23	CI
Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023	23-10-16	CI
Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types	23-08-23	CI
Medigene AG Provides Revenue Guidance for 2023	23-08-17	CI
Transcript : Medigene AG, H1 2023 Earnings Call, Aug 17, 2023	23-08-17
Medigene AG Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Medigene AG Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies	23-06-22	CI
Transcript : Medigene AG - Special Call	23-06-20
Medigene AG Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs	23-06-01	CI

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Sector

Biotechnology & Medical Research

Calendar

2024-05-21 - Benchmark Healthcare House Virtual Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Medigene AG

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.405 EUR

Average target price

2.675 EUR

Spread / Average Target

+90.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MEDIGENE AG	-7.87%	37.78M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs

Medigene AG

Equities

MDG1

DE000A1X3W00

Biotechnology & Medical Research

Medigene AG Reaffirms Revenue Guidance for the Year 2020

Latest news about Medigene AG

Chart Medigene AG

Company Profile

Income Statement Evolution

Ratings for Medigene AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs